Auxilium Pharmaceuticals, Inc. (AUXL) Reports Q4 Loss of $0.25, Offers FY12 Sales Guidance

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) reported Q4 EPS of ($0.25), $0.09 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $73.3 million versus the consensus estimate of $73.53 million.

Auxilium Pharmaceuticals, Inc. sees FY2012 revenue of $283-$305 million, versus the consensus of $301.76 million.

For earnings history and earnings-related data on Auxilium Pharmaceuticals, Inc. (AUXL) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Burry doubles down on Nebius short after stock surges 34% on earnings
• Innovative Solutions & Support (ISSC) Tops Q3 EPS by 10c
• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c